ArticleMaterials (Basel, Switzerland)2026
Compositional Characterization of Ultrafine Composite Powder as a Novel Supplementary Cementitious Material.
Article in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To investigate the application potential of ultrafine composite powder (UCP) as a novel supplementary cementitious material to replace ground granulated blast-furnace slag (GBFS) in cement-based materials and its underlying mechanism, this study first compared the activity differences between UCP and GBFS and their effects on mortar workability. Subsequently, multiple characterization techniques including XRF, XRD, TG/DTG, FTIR, mapping, SEM-EDS, and BET were employed to systematically examine the morphology, composition, particle size distribution, and pore structure characteristics of the two powders. Results show that UCP exhibits slightly higher 3 d and 28 d strength activity indices than GBFS, but contributes less to strength progression between 3 and 28 days. In terms of chemical composition, UCP contains lower combined CaO + MgO + Al
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.